Pro-Dex Inc

Pro-Dex Inc(PDEX)股票分析

$62.555

-2.221 (-3.55%)收盤時

Loading chart…
High
64.890
Open
64.890
VWAP
63.21
Vol
56.66K
Mkt Cap
64.62M
Low
62.170
Amount
3.58M
EV/EBITDA, TTM
15.67

Pro-Dex, Inc. specializes in the design, development, and manufacture of autoclavable, battery-powered and electric, multi-function surgical drivers and shavers used primarily in the orthopedic, thoracic, and maxocranial facial markets. The Company has patented adoptive torque-limiting software and sealing solutions, which appeal to its customers, primarily medical device distributors. It also manufactures and sells rotary air motors to a range of industries. The Company’s medical device products utilize designs developed by it primarily under development and supply agreements and are machined in its Irvine, California facility, and assembled in its Tustin, California facility, as are its rotary air motors. Its medical device products are sold primarily to original equipment manufacturers and its air motors are sold primarily to a range of distributors and end users. It manufactures machined sub-assemblies and also produces parts and assemblies for aerospace and defense systems.

AI analysis of Pro-Dex Inc (PDEX)

hold

Pro-Dex Inc is currently not a strong buy due to its recent price decline and low RSI, but it shows potential for recovery in the long term. The current price is $62.55, with a 5-day change of -4.74%, indicating short-term weakness. However, the year-to-date change of +65.84% suggests strong long-term performance. The forward P/E ratio of 22.83 indicates that the stock may be overvalued at this price point, and the RSI of 30.09 suggests it is oversold, which could lead to a rebound. The main risk is the recent decline in revenue growth, with Q2 revenue at $18.66 million, which is lower than expected, impacting investor sentiment.

Analyst Ratings (1)

Buy
1 Buy
0 Hold
0 Sell
Current: 62.56
最低
平均
最高

Ascendiant Capital

2024-11-11

目標價

$52

Strong Buy

Ascendiant Capital

2024-09-09

目標價

$30

Strong Buy

估值指標

The current forward P/E ratio for Pro-Dex Inc (PDEX) is 22.83, compared to its 5-year average forward P/E of 17.45.

Forward P/E

Fair
5Y Average P/E
17.45
Current P/E
22.83
高估
23.50
低估
11.40

Forward EV/EBITDA

Overvalued
5Y Average EV/EBITDA
10.44
Current EV/EBITDA
15.67
高估
13.45
低估
7.43

Forward P/S

Overvalued
5Y Average P/S
1.70
Current P/S
2.56
高估
2.19
低估
1.21

Alphio AI Price Scenarios for PDEX

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%PDEX

$55.23

情境價格

B

Base

Base · 50%PDEX

$51.89

情境價格

B

Bear

Bear · 25%PDEX

$51.20

情境價格

PDEX FAQ — answered by Alphio AI

Pro-Dex, Inc. specializes in the design, development, and manufacture of autoclavable, battery-powered and electric, multi-function surgical drivers and shavers used primarily in the orthopedic, thoracic, and maxocranial facial markets. The Company has patented adoptive torque-limiting software and sealing solutions, which appeal to its customers, primarily medical device distributors. It also manufactures and sells rotary air motors to a range of industries. The Company’s medical device products utilize designs developed by it primarily under development and supply agreements and are machined in its Irvine, California facility, and assembled in its Tustin, California facility, as are its rotary air motors. Its medical device products are sold primarily to original equipment manufacturers and its air motors are sold primarily to a range of distributors and end users. It manufactures machined sub-assemblies and also produces parts and assemblies for aerospace and defense systems. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Pro-Dex Inc is currently not a strong buy due to its recent price decline and low RSI, but it shows potential for recovery in the long term. The current price is $62.55, with a 5-day change of -4.74%, indicating short-term weakness. However, the year-to-date change of +65.84% suggests strong long-term performance. The forward P/E ratio of 22.83 indicates that the stock may be overvalued at this price point, and the RSI of 30.09 suggests it is oversold, which could lead to a rebound. The main risk is the recent decline in revenue growth, with Q2 revenue at $18.66 million, which is lower than expected, impacting investor sentiment.

1 analysts cover PDEX: 1 rate it Buy, 0 Hold and 0 Sell.

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

免費開始